Initial remission duration of less than 1 year is no longer an adverse prognostic factor for patients with relapsed HL undergoing high dose therapy and autologous stem cell transplant: Results of a combined analysis from two large transplant centers Meeting Abstract


Authors: Moskowitz, A. J.; Sweetenham, J.; Bolwell, B. J.; Maragulia, J. C.; Vanak, J. M.; Moskowitz, C. H.; Smith, S.
Abstract Title: Initial remission duration of less than 1 year is no longer an adverse prognostic factor for patients with relapsed HL undergoing high dose therapy and autologous stem cell transplant: Results of a combined analysis from two large transplant centers
Meeting Title: 51st Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 114
Issue: 22
Meeting Dates: 2009 Dec 5-8
Meeting Location: New Orleans, LA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2009-11-20
Start Page: 1325
End Page: 1326
Language: English
ACCESSION: WOS:000272725804078
PROVIDER: wos
PUBMED: 22276299
Notes: Meeting Abstract: 3413 -- Source: Wos
MSK Authors
  1. Craig Moskowitz
    375 Moskowitz
  2. Alison Moskowitz
    148 Moskowitz
  3. Jill M Vanak
    14 Vanak
Related MSK Work